Acquisition potential Array Biostatistics was acquired by Cato SMS in September 2020, suggesting a strategic pull toward expanding clinical research capabilities. This history indicates potential alignment opportunities with CROs seeking to broaden biostatistical and programming services for larger, integrated programs.

Niche specialization As a small CRO focused on biostatistics and statistical programming for biopharmaceuticals, Array BIostatistics can be positioned as a partner for highly specialized, cost-efficient statistical support, especially for Phase I–III programs requiring expert analytics with personalized service.

Tech-enabled efficiency Utilizing AWS, Route 53, Box and other cloud and collaboration tools suggests scalability and secure data handling. This can be leveraged to offer compliant, fast-turnaround statistical programming work and seamless data management for sponsors seeking modern, efficient CRO partnerships.

Growth-friendly positioning With revenue under one million and a lean team, there is an opportunity to offer scalable resourcing models, such as on-demand biostatisticians and modular programming support, to mid-market sponsors looking for flexible cost structures without large incumbent CRO commitments.

Competitive collaboration The acquisition history and presence among mid-to-large CROs imply potential for collaboration or subcontracting arrangements. Position Array as a nimble, high-touch partner capable of integrating with larger programs or filling gaps in specialized statistical expertise.